Trump announces trade deal with EU following months of negotiations
B Capital Global Growth III, L.P. purchased 1,333,333 shares of CARLSMED, INC. (NASDAQ:CARL) common stock at $15 per share, for a total value of $19,999,995. The purchase price sits near CARL’s 52-week high of $15.20, with the company currently valued at $384.49 million. According to InvestingPro data, CARL maintains strong liquidity with a current ratio of 6.48, though it remains unprofitable over the last twelve months.
On July 24, 2025, B Capital Global Growth III, L.P. also acquired 3,680,506 shares of Common Stock, B Capital Healthcare I, L.P. acquired 2,376,472 shares of Common Stock and Hornet Co-Invest, L.P. acquired 931,452 shares of Common Stock, all through the conversion of preferred stock.
Additionally, on the same day, B Capital Global Growth III, L.P. converted 1,445,020 shares of Series B Preferred Stock and 2,235,486 shares of Series C Preferred Stock into common stock. B Capital Healthcare I, L.P. converted 1,445,020 shares of Series B Preferred Stock and 931,452 shares of Series C Preferred Stock into common stock. Hornet Co-Invest, L.P. converted 931,452 shares of Series C Preferred Stock into common stock.
In other recent news, Carlsmed , Inc. has successfully launched its initial public offering (IPO), pricing the shares at $15.00 each. The company offered 6,700,000 shares of common stock, with trading commencing on the Nasdaq Global Select Market under the symbol "CARL." This IPO is expected to generate gross proceeds of approximately $100.5 million, before accounting for underwriting discounts, commissions, and other related expenses. The offering is anticipated to close soon, pending customary closing conditions. Additionally, underwriters have a 30-day option to purchase up to an additional 1,005,000 shares at the initial offering price. These recent developments mark a significant milestone for Carlsmed as it enters the public market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.